GW Pharmaceuticals SWOT Analysis, Competitors, STP & USP

GW Pharmaceuticals

Biopharmaceutical

Pharma and Healthcare

-

Its MS treatment product

Healthcare

People suffering from multiple sclerosis, epilepsy and cancer

Focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform

Below are the Strengths in the SWOT Analysis of GW Pharmaceuticals:

1. GW Pharmaceuticals has the only cultivation license in the United Kingdom from the Home Office and theMHRA, to cultivate cannabis from seeds and clones to conduct scientific research concerning the medicinal uses of the plant
2. GW Pharmaceuticals concluded a partnership with Bayer for the distribution of Sativex in North America
3. GW is researching a large number of cannabinoids, each of which has different effects and applications

4.Collaboration with various educational institutes for R&D.

5. Strong expertise in the industry

Here are the weaknesses in the GW Pharmaceuticals SWOT Analysis:

1. Health issues due to side effects of cannabis
2.Human rights issues as cannabis is considered as a harmful drug
3.Legal issues in cultivating medical cannabis

4.Requires very high quality control in cultivating medical cannabis

Following are the Opportunities in GW Pharmaceuticals SWOT Analysis:

1. Its cannabis-based product, Epidiolex, developed for experimental treatment of epilepsy, will undergo stage-two trials in the US in 2014
2. Tie ups with large hospitals can be a huge opportunity
3.Scope of entering into other segments of pharmaceuticals

The threats in the SWOT Analysis of GW Pharmaceuticals are as mentioned:

1.It has only one major drug Sativex, contribute maximum to the revenue
2.Need for continuous innovation
3.Stringent government rules and quality control measures

Below are the top 3 GW Pharmaceuticals competitors:

1.Shire UK
2.Teva UK Limited
3.Meda Pharmaceuticals UK